Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement

COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

2,171 shares at DKK 1,025.00,
2,790 shares at DKK 1,032.00,
98 shares at DKK 1,161.00,
729 shares at DKK 1,334.50,
343 shares at DKK 1,362.50,
549 shares at DKK 1,408.00,
179 shares at DKK 1,432.00, and
100 shares at DKK 1,615.00.

Proceeds to the company are approximately DKK 7.8 million. The increase corresponds to approximately 0.01% of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No. 198 of February 26, 2024, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 66,129,923 which is made up of 66,129,923 shares of a nominal value of DKK 1 each, corresponding to 66,129,923 votes.

About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies, and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines.